This was a large observational cohort study using real-world data on pregnant women diagnosed with psoriasis. Researchers compared pregnancy and neonatal outcomes among women exposed to biologic therapies (such as TNF inhibitors and newer targeted biologics) before and/or during pregnancy versus those not exposed. Sample size was substantial (thousands of pregnancies), allowing comparison across different biologic agents and timing of exposure. Primary endpoints included major congenital malformations, spontaneous abortion (miscarriage), preterm birth, low birth weight, and neonatal complications.
Biologic use in pregnancy was not associated with an increased risk of major congenital malformations compared with non-biologic exposure in women with psoriasis; rates were similar between groups and differences were not statistically significant. Risks of spontaneous abortion, stillbirth, preterm birth, and low birth weight were also comparable, with effect estimates generally close to 1.0 and confidence intervals crossing or near 1.0. Some subgroup analyses by specific biologic class (e.g., TNF inhibitors vs newer agents) did not show clear signals of harm, although numbers for newer drugs were smaller. Overall, the data suggest no clear increase in serious adverse maternal or neonatal outcomes linked to biologic exposure, especially for agents with more pregnancy experience like TNF inhibitors.
This was an observational, not randomized, study, so residual confounding (especially by disease severity, lifestyle factors, and comorbidities) is likely. Medication exposure was based on prescriptions or claims, which may not perfectly reflect actual use, dose, or adherence, and timing of exposure relative to conception could be imprecise. Newer biologic classes had much smaller numbers, limiting power to detect rare risks or class-specific effects, and long-term outcomes in children (immune, growth, neurodevelopment) were not assessed. The population may not fully represent all ethnic groups, women with complex autoimmune overlaps, or those with significant fertility challenges, so results should be applied cautiously and always individualized with clinician guidance.
For women with moderate-to-severe psoriasis, this study supports the growing body of evidence that many biologics, particularly TNF inhibitors, may be relatively safe in pregnancy when clinically indicated. The use of real-world registry or claims data increases generalizability but introduces potential confounding by disease severity, comorbid conditions, and differences in care. The lack of a strong dose–response or timing-related signal for adverse events is reassuring, but newer IL-17/IL-23 agents still have more limited pregnancy data and should be interpreted with caution. These findings align with prior rheumatology and dermatology pregnancy registries, but do not fully settle questions about long-term child immune development or subtle neurodevelopmental effects, which remain under-studied.
Women with psoriasis who need biologics and are planning pregnancy can discuss this evidence with their care team to weigh the risks of untreated disease versus medication exposure. Good preconception counseling should include disease control, medication review, timing of conception, nutritional status, and screening for metabolic and autoimmune comorbidities common in psoriasis (e.g., insulin resistance, thyroid issues). Cycle tracking and fertility biomarkers (such as cervical mucus observations and luteal phase length) can be integrated with dermatology care to time conception during more stable disease and lower medication doses when safely possible. Any medication changes—starting, stopping, or switching biologics—should be done gradually and under close supervision to avoid disease flares that may themselves impact pregnancy and overall health.
For someone with psoriasis who is pregnant or hoping to conceive, this study suggests that many biologic medications did not increase the risk of major birth defects or pregnancy loss compared with women with psoriasis who did not use these drugs. This is reassuring because uncontrolled inflammation and flares can also affect your overall health and potentially your pregnancy. A restorative approach looks beyond the skin to your whole system—immune balance, hormones, metabolism, gut health, stress, and cycle patterns—while also using the safest effective treatments when needed. Work closely with your dermatologist and a fertility-focused clinician to map your cycles, check for root causes and coexisting conditions, and choose a treatment plan that respects both your skin health and your fertility goals.
These data reinforce prior registry findings that TNF inhibitors and some other biologics for psoriasis do not substantially elevate risk for major congenital malformations or key obstetric outcomes, particularly when exposure continues through early pregnancy. From a restorative standpoint, clinicians should concurrently evaluate endocrine–metabolic comorbidities (insulin resistance, PCOS, thyroid dysfunction, obesity, vitamin D deficiency), subclinical inflammation (hs-CRP), and autoimmunity that may influence both psoriasis and fertility. Suggested labs: fasting insulin/glucose or HOMA-IR, lipid panel, TSH with antibodies, 25(OH)D, hs-CRP, CBC, ferritin, B12/folate, and screening for celiac or other autoimmune disease when indicated. Integrate cycle charting (luteal phase adequacy, mid-luteal progesterone, ovulation timing) into medication planning; consider aiming for disease stability preconception and, when appropriate, continuing better-studied agents (e.g., certain TNF inhibitors) rather than switching late. Counsel about infant vaccine timing if third-trimester biologic exposure occurred, per existing rheum/derm guidelines. Emphasize shared decision-making, documenting uncertainty for newer biologics and discussing the trade-offs of disease flare versus potential but unproven fetal risk.
Educational insights, not a diagnosis or individualized treatment advice. Discuss findings with your own clinician. Visit Reproductive Health Insights to explore fertility resources.